GeneDx Holdings (WGSWW) Other Accumulated Expenses (2020 - 2026)

GeneDx Holdings (WGSWW) has 7 years of Other Accumulated Expenses data on file, last reported at $35.9 million in Q1 2026.

• Other Accumulated Expenses for Q1 2026 came in at $35.9 million, up 46.4% year-over-year; the trailing twelve-month figure through Mar 2026 was $35.9 million (up 46.4% YoY), and the FY2025 annual result was $46.9 million, up 128.6% from the prior year.
• Other Accumulated Expenses eased to $35.9 million in Q1 2026 per WGSWW's latest filing, from $46.9 million in the prior quarter.
• Over five years, Other Accumulated Expenses peaked at $81.6 million in Q2 2022 and troughed at $727000.0 in Q3 2024.
• A 5-year average of $30.4 million and a median of $23.4 million in 2022 frame the typical range for Other Accumulated Expenses.
• The sharpest annual moves came in 2024 and 2025: Other Accumulated Expenses sank 96.67% in 2024, then soared 4419.67% in 2025.
• A 5-year view of Other Accumulated Expenses shows it stood at $49.7 million in 2022, then sank by 67.13% to $16.3 million in 2023, then advanced by 25.48% to $20.5 million in 2024, then soared by 128.6% to $46.9 million in 2025, then decreased by 23.28% to $35.9 million in 2026.
• Business Quant data shows WGSWW's Other Accumulated Expenses at $35.9 million in Q1 2026, $46.9 million in Q4 2025, and $32.9 million in Q3 2025.